Видео ютуба по тегу Del(17P)

Deletion 17p in Myeloma: Key Facts You Should Know - del (17p)
Deletion 17p in Myeloma: Key Facts You Should Know - del (17p)
Myeloma Crowd Radio/MCRI: Dr. Robert Orlowski, MD, PhD, Del 17p
Myeloma Crowd Radio/MCRI: Dr. Robert Orlowski, MD, PhD, Del 17p
Managing multiple myeloma patients with del(17p)
Managing multiple myeloma patients with del(17p)
Myeloma: impact of Del 17p on transplantation outcomes
Myeloma: impact of Del 17p on transplantation outcomes
The importance of del(17p) as a prognostic factor in myeloma
The importance of del(17p) as a prognostic factor in myeloma
Case 2: Choosing Treatment for CLL With Del(17p)
Case 2: Choosing Treatment for CLL With Del(17p)
Case 2: Newly Diagnosed CLL; Del(17p)
Case 2: Newly Diagnosed CLL; Del(17p)
Debate: Optimal approach for the management of CLL patients with del(17p) - Ibrutinib
Debate: Optimal approach for the management of CLL patients with del(17p) - Ibrutinib
Key prognostic markers in CLL: TP53, del(17p), and high complexity karyotype
Key prognostic markers in CLL: TP53, del(17p), and high complexity karyotype
Case 2: Frontline Treatments for CLL With Del(17p)
Case 2: Frontline Treatments for CLL With Del(17p)
Efficacy of ibrutinib in the treatment of CLL patients with del(17p) and TP53 mutation
Efficacy of ibrutinib in the treatment of CLL patients with del(17p) and TP53 mutation
SEQUOIA: zanubrutinib-based treatment for CLL with del(17p)
SEQUOIA: zanubrutinib-based treatment for CLL with del(17p)
Starting to share my journey with MM del 17p.
Starting to share my journey with MM del 17p.
Занубрутиниб с делецией (17p) при хроническом лимфолейкозе (ХЛЛ) и склерозе лимфобластного лейкоз...
Занубрутиниб с делецией (17p) при хроническом лимфолейкозе (ХЛЛ) и склерозе лимфобластного лейкоз...
Myeloma Crowd Radio/MCRI: Dr. Robert Orlowski, MD, PhD, Del 17p
Myeloma Crowd Radio/MCRI: Dr. Robert Orlowski, MD, PhD, Del 17p
Обинутузумаб, ибрутиниб и венетоклакс при ХЛЛ 17p/TP53 - доктор Стефан Стилгенбауэр, ASH, 2022 г.
Обинутузумаб, ибрутиниб и венетоклакс при ХЛЛ 17p/TP53 - доктор Стефан Стилгенбауэр, ASH, 2022 г.
Targeting high-risk patients with del(17p) - Ghia
Targeting high-risk patients with del(17p) - Ghia
Оптимизация терапии хронического лимфолейкоза с использованием теории игр
Оптимизация терапии хронического лимфолейкоза с использованием теории игр
Treatment recommendations for patients with CLL with del(17p) and TP53 aberrations
Treatment recommendations for patients with CLL with del(17p) and TP53 aberrations
Debate: Optimal approach for the management of CLL patients with del(17p) - Novel Agents
Debate: Optimal approach for the management of CLL patients with del(17p) - Novel Agents